Cadila Healthcare Q3 results: Net profit up 41% to Rs 527 crore
SECTIONS
Last Updated: Feb 05, 2021, 04:02 PM IST
Share
Synopsis
The company had posted a net profit of Rs 373.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.
Consolidated revenue of the company stood at Rs 3,795.6 crore for the quarter under consideration. It was Rs 3,638.1 crore for the same period a year ago, it added.
Related
NSE
Drug firm
Cadila Healthcare on Friday reported a 41 per cent rise in its consolidated net profit to Rs 527.2 crore for the quarter ended December 2020 on account of robust sales in all segments.
Synopsis
Zydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon USFDA approval.
ThinkStock Photos
Representative Image
New Delhi: Zydus Cadila on Thursday said the US health regulator has granted orphan drug designation (ODD) to its Saroglitazar Mg used for the treatment of patients with Primary Biliary Cholangitis (PBC), a liver disease. The United States Food and Drug Administration (USFDA) has granted ODD to Saroglitazar Mg,
Cadila Healthcare said in a regulatory filing. Zydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon USFDA approval.
Synopsis
Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV.
Agencies
Drug firm
Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences. Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 200 mg/300 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.
Unichem Labs gets American drug regulator s nod to market generic Celecoxib capsules
SECTIONS
Last Updated: Jan 13, 2021, 02:03 PM IST
Share
Synopsis
The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA), Unichem said in a filing to BSE.
ThinkStock Photos
NEW DELHI: Drug firm
Unichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules used for treatment of osteoarthritis, rheumatoid arthritis and acute pain. The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA), Unichem said in a filing to BSE.
Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia Topical Solution, 10%,
of Bausch Health Americas, Inc.
Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of USD 222.9 million in the U.
S.
(IQVIA MAT September 2020).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offer